KR20100093621A - 사포게닌 및 그 유도체의 치료 방법 및 용도 - Google Patents

사포게닌 및 그 유도체의 치료 방법 및 용도 Download PDF

Info

Publication number: KR20100093621A
Authority: KR; South Korea
Prior art keywords: alkyl; group; alkyl group; pharmaceutically acceptable; unsubstituted
Prior art date: 2002-03-27

Application number

KR1020107017081A

Other languages

English (en)

Korean (ko)

Inventor

다일 리스

필 구닝

안토니아 오르시

종친 시아

야얼 휴

Original Assignee

파이토팜 피엘씨

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-03-27

Filing date

2003-03-27

Publication date

2010-08-25

2002-03-27 Priority claimed from ARP020101170A external-priority patent/AR033079A1/es

2003-03-27 Application filed by 파이토팜 피엘씨 filed Critical 파이토팜 피엘씨

2010-08-25 Publication of KR20100093621A publication Critical patent/KR20100093621A/ko

Links

WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 title claims description 44
NWMIYTWHUDFRPL-UHFFFAOYSA-N sapogenin Natural products COC(=O)C1(CO)C(O)CCC2(C)C1CCC3(C)C2CC=C4C5C(C)(O)C(C)CCC5(CCC34C)C(=O)O NWMIYTWHUDFRPL-UHFFFAOYSA-N 0.000 title claims description 37
238000000034 method Methods 0.000 title claims description 22
230000001225 therapeutic effect Effects 0.000 title description 4
150000001875 compounds Chemical class 0.000 claims abstract description 117
230000004770 neurodegeneration Effects 0.000 claims abstract description 61
230000001149 cognitive effect Effects 0.000 claims abstract description 25
230000002232 neuromuscular Effects 0.000 claims abstract description 22
230000007850 degeneration Effects 0.000 claims abstract description 19
230000004064 dysfunction Effects 0.000 claims abstract description 9
230000003637 steroidlike Effects 0.000 claims abstract description 7
INLFWQCRAJUDCR-IQVMEADQSA-N (1R,2S,4S,5'S,6R,7S,8R,9S,12S,13S)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-oxane] Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CCCCC4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@H](C)CO1 INLFWQCRAJUDCR-IQVMEADQSA-N 0.000 claims abstract description 3
GMBQZIIUCVWOCD-UQHLGXRBSA-N (25R)-5beta-spirostan-3beta-ol Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)C[C@H]4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 GMBQZIIUCVWOCD-UQHLGXRBSA-N 0.000 claims description 186
125000000217 alkyl group Chemical group 0.000 claims description 151
RTMWIZOXNKJHRE-UHFFFAOYSA-N Tigogenin Natural products CC1COC2CC(C)(OC12)C3CCC4C5CCC6CC(O)CCC6(C)C5CCC34C RTMWIZOXNKJHRE-UHFFFAOYSA-N 0.000 claims description 132
229950002323 smilagenin Drugs 0.000 claims description 93
ZINJLDJMHCUBIP-UHFFFAOYSA-N ethametsulfuron-methyl Chemical compound CCOC1=NC(NC)=NC(NC(=O)NS(=O)(=O)C=2C(=CC=CC=2)C(=O)OC)=N1 ZINJLDJMHCUBIP-UHFFFAOYSA-N 0.000 claims description 88
150000003839 salts Chemical class 0.000 claims description 78
-1 R 21 Chemical compound 0.000 claims description 67
125000002252 acyl group Chemical group 0.000 claims description 63
125000005843 halogen group Chemical group 0.000 claims description 58
239000003814 drug Substances 0.000 claims description 41
229940079593 drug Drugs 0.000 claims description 39
GMBQZIIUCVWOCD-SGKIHABASA-N epismilagenin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@@H](O)C[C@H]4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 GMBQZIIUCVWOCD-SGKIHABASA-N 0.000 claims description 38
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 37
102000005962 receptors Human genes 0.000 claims description 36
108020003175 receptors Proteins 0.000 claims description 36
201000010099 disease Diseases 0.000 claims description 33
239000000203 mixture Substances 0.000 claims description 25
208000011580 syndromic disease Diseases 0.000 claims description 24
DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 claims description 18
125000001424 substituent group Chemical group 0.000 claims description 17
229910052799 carbon Inorganic materials 0.000 claims description 16
239000008103 glucose Substances 0.000 claims description 16
239000000651 prodrug Substances 0.000 claims description 15
229940002612 prodrug Drugs 0.000 claims description 15
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 15
108010025020 Nerve Growth Factor Proteins 0.000 claims description 14
102000007072 Nerve Growth Factors Human genes 0.000 claims description 13
230000000926 neurological effect Effects 0.000 claims description 13
210000000056 organ Anatomy 0.000 claims description 13
235000000346 sugar Nutrition 0.000 claims description 13
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 11
150000001721 carbon Chemical group 0.000 claims description 11
206010003694 Atrophy Diseases 0.000 claims description 10
230000037444 atrophy Effects 0.000 claims description 10
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 9
241000282412 Homo Species 0.000 claims description 9
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 9
QNAYBMKLOCPYGJ-UHFFFAOYSA-M alaninate Chemical compound CC(N)C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-M 0.000 claims description 9
150000001719 carbohydrate derivatives Chemical class 0.000 claims description 9
150000001720 carbohydrates Chemical group 0.000 claims description 9
235000014633 carbohydrates Nutrition 0.000 claims description 9
FFEARJCKVFRZRR-UHFFFAOYSA-M methioninate Chemical compound CSCCC(N)C([O-])=O FFEARJCKVFRZRR-UHFFFAOYSA-M 0.000 claims description 9
201000006938 muscular dystrophy Diseases 0.000 claims description 9
239000003900 neurotrophic factor Substances 0.000 claims description 9
208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 8
208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 8
208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 8
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 8
208000018737 Parkinson disease Diseases 0.000 claims description 8
QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 claims description 8
125000003118 aryl group Chemical group 0.000 claims description 8
125000004432 carbon atom Chemical group C* 0.000 claims description 8
QYIXCDOBOSTCEI-NWKZBHTNSA-N coprostanol Chemical compound C([C@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-NWKZBHTNSA-N 0.000 claims description 8
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 7
SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 7
CIBAPVLFORANSS-OHEGQEBBSA-N SMILAGENONE Chemical compound CC1C([C@]2(CCC3[C@@]4(C)CCC(=O)C[C@H]4CCC3C2C2)C)C2OC11CC[C@@H](C)CO1 CIBAPVLFORANSS-OHEGQEBBSA-N 0.000 claims description 7
CIBAPVLFORANSS-UHFFFAOYSA-N Smilagenone Natural products CC1C(C2(CCC3C4(C)CCC(=O)CC4CCC3C2C2)C)C2OC11CCC(C)CO1 CIBAPVLFORANSS-UHFFFAOYSA-N 0.000 claims description 7
PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 7
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 7
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 7
230000007547 defect Effects 0.000 claims description 7
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 7
229930182490 saponin Natural products 0.000 claims description 7
FZFIXAWDCINUNL-HUJMDDBMSA-N (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O FZFIXAWDCINUNL-HUJMDDBMSA-N 0.000 claims description 6
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims description 6
125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 6
150000002016 disaccharides Chemical class 0.000 claims description 6
150000002772 monosaccharides Chemical group 0.000 claims description 6
201000001119 neuropathy Diseases 0.000 claims description 6
230000007823 neuropathy Effects 0.000 claims description 6
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 6
INLFWQCRAJUDCR-LYLBMTSKSA-N spirostane Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CCCCC4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 INLFWQCRAJUDCR-LYLBMTSKSA-N 0.000 claims description 6
239000000126 substance Substances 0.000 claims description 6
150000004043 trisaccharides Chemical class 0.000 claims description 6
SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 5
235000013361 beverage Nutrition 0.000 claims description 5
235000015872 dietary supplement Nutrition 0.000 claims description 5
206010028417 myasthenia gravis Diseases 0.000 claims description 5
239000008194 pharmaceutical composition Substances 0.000 claims description 5
208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 claims description 4
206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 4
SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims description 4
PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims description 4
208000001089 Multiple system atrophy Diseases 0.000 claims description 4
208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 claims description 4
208000005881 bovine spongiform encephalopathy Diseases 0.000 claims description 4
125000000837 carbohydrate group Chemical group 0.000 claims description 4
150000001732 carboxylic acid derivatives Chemical group 0.000 claims description 4
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
208000033808 peripheral neuropathy Diseases 0.000 claims description 4
ZQLNRLOILKALSH-OTDRECOKSA-N (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal (2R,3R,4S,5S)-2,3,4,5-tetrahydroxyhexanal Chemical compound C[C@H](O)[C@H](O)[C@@H](O)[C@@H](O)C=O.C[C@H](O)[C@H](O)[C@@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O ZQLNRLOILKALSH-OTDRECOKSA-N 0.000 claims description 3
YAHHFDSODKFKOV-OTEWLTGOSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;(2r,3r,4s,5s)-2,3,4,5-tetrahydroxyhexanal Chemical compound C[C@H](O)[C@H](O)[C@@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O YAHHFDSODKFKOV-OTEWLTGOSA-N 0.000 claims description 3
AUTALUGDOGWPQH-SPWJBRMPSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;(2s,3r,4r)-2,3,4,5-tetrahydroxypentanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O AUTALUGDOGWPQH-SPWJBRMPSA-N 0.000 claims description 3
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 3
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
208000013586 Complex regional pain syndrome type 1 Diseases 0.000 claims description 3
AVGPOAXYRRIZMM-UHFFFAOYSA-N D-Apiose Natural products OCC(O)(CO)C(O)C=O AVGPOAXYRRIZMM-UHFFFAOYSA-N 0.000 claims description 3
GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 claims description 3
ASNHGEVAWNWCRQ-LJJLCWGRSA-N D-apiofuranose Chemical compound OC[C@@]1(O)COC(O)[C@@H]1O ASNHGEVAWNWCRQ-LJJLCWGRSA-N 0.000 claims description 3
ASNHGEVAWNWCRQ-UHFFFAOYSA-N D-apiofuranose Natural products OCC1(O)COC(O)C1O ASNHGEVAWNWCRQ-UHFFFAOYSA-N 0.000 claims description 3
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 3
229930091371 Fructose Natural products 0.000 claims description 3
239000005715 Fructose Substances 0.000 claims description 3
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 3
PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
208000003923 Hereditary Corneal Dystrophies Diseases 0.000 claims description 3
208000023105 Huntington disease Diseases 0.000 claims description 3
SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 3
206010068871 Myotonic dystrophy Diseases 0.000 claims description 3
201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 claims description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
229930006000 Sucrose Natural products 0.000 claims description 3
241000282485 Vulpes vulpes Species 0.000 claims description 3
239000000556 agonist Substances 0.000 claims description 3
125000005115 alkyl carbamoyl group Chemical group 0.000 claims description 3
125000004448 alkyl carbonyl group Chemical group 0.000 claims description 3
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 3
229940121363 anti-inflammatory agent Drugs 0.000 claims description 3
239000002260 anti-inflammatory agent Substances 0.000 claims description 3
PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims description 3
125000005116 aryl carbamoyl group Chemical group 0.000 claims description 3
208000006673 asthma Diseases 0.000 claims description 3
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 3
239000003557 cannabinoid Substances 0.000 claims description 3
229930003827 cannabinoid Natural products 0.000 claims description 3
239000000812 cholinergic antagonist Substances 0.000 claims description 3
206010011005 corneal dystrophy Diseases 0.000 claims description 3
206010014599 encephalitis Diseases 0.000 claims description 3
229930182830 galactose Natural products 0.000 claims description 3
239000008101 lactose Substances 0.000 claims description 3
201000006417 multiple sclerosis Diseases 0.000 claims description 3
208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 3
239000001397 quillaja saponaria molina bark Substances 0.000 claims description 3
239000005720 sucrose Substances 0.000 claims description 3
239000003477 4 aminobutyric acid receptor stimulating agent Substances 0.000 claims description 2
208000031277 Amaurotic familial idiocy Diseases 0.000 claims description 2
JYLQYOXTEAKERB-UHFFFAOYSA-N Anzurogenin D Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4(O)C(O)CC3C2C2)C)C2OC11CCC(C)CO1 JYLQYOXTEAKERB-UHFFFAOYSA-N 0.000 claims description 2
102000007370 Ataxin2 Human genes 0.000 claims description 2
108010032951 Ataxin2 Proteins 0.000 claims description 2
208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 2
208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 2
208000034577 Benign intracranial hypertension Diseases 0.000 claims description 2
206010053684 Cerebrohepatorenal syndrome Diseases 0.000 claims description 2
208000010200 Cockayne syndrome Diseases 0.000 claims description 2
206010010904 Convulsion Diseases 0.000 claims description 2
208000011990 Corticobasal Degeneration Diseases 0.000 claims description 2
208000032131 Diabetic Neuropathies Diseases 0.000 claims description 2
LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 claims description 2
JRWZLRBJNMZMFE-UHFFFAOYSA-N Dobutamine Chemical compound C=1C=C(O)C(O)=CC=1CCNC(C)CCC1=CC=C(O)C=C1 JRWZLRBJNMZMFE-UHFFFAOYSA-N 0.000 claims description 2
206010014612 Encephalitis viral Diseases 0.000 claims description 2
208000024412 Friedreich ataxia Diseases 0.000 claims description 2
201000011240 Frontotemporal dementia Diseases 0.000 claims description 2
208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 2
229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 2
206010019196 Head injury Diseases 0.000 claims description 2
208000001953 Hypotension Diseases 0.000 claims description 2
208000018127 Idiopathic intracranial hypertension Diseases 0.000 claims description 2
102000003996 Interferon-beta Human genes 0.000 claims description 2
108090000467 Interferon-beta Proteins 0.000 claims description 2
206010048911 Lissencephaly Diseases 0.000 claims description 2
208000002569 Machado-Joseph Disease Diseases 0.000 claims description 2
102000010909 Monoamine Oxidase Human genes 0.000 claims description 2
108010062431 Monoamine oxidase Proteins 0.000 claims description 2
208000009433 Moyamoya Disease Diseases 0.000 claims description 2
102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 claims description 2
108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 claims description 2
208000014060 Niemann-Pick disease Diseases 0.000 claims description 2
208000003435 Optic Neuritis Diseases 0.000 claims description 2
206010056332 Panencephalitis Diseases 0.000 claims description 2
208000000609 Pick Disease of the Brain Diseases 0.000 claims description 2
208000000474 Poliomyelitis Diseases 0.000 claims description 2
208000036757 Postencephalitic parkinsonism Diseases 0.000 claims description 2
102000029797 Prion Human genes 0.000 claims description 2
108091000054 Prion Proteins 0.000 claims description 2
208000005587 Refsum Disease Diseases 0.000 claims description 2
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 2
208000009415 Spinocerebellar Ataxias Diseases 0.000 claims description 2
201000003622 Spinocerebellar ataxia type 2 Diseases 0.000 claims description 2
206010048327 Supranuclear palsy Diseases 0.000 claims description 2
206010044688 Trisomy 21 Diseases 0.000 claims description 2
208000026911 Tuberous sclerosis complex Diseases 0.000 claims description 2
208000002552 acute disseminated encephalomyelitis Diseases 0.000 claims description 2
239000000808 adrenergic beta-agonist Substances 0.000 claims description 2
208000030597 adult Refsum disease Diseases 0.000 claims description 2
239000003288 aldose reductase inhibitor Substances 0.000 claims description 2
229940090865 aldose reductase inhibitors used in diabetes Drugs 0.000 claims description 2
230000001078 anti-cholinergic effect Effects 0.000 claims description 2
230000003110 anti-inflammatory effect Effects 0.000 claims description 2
229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 claims description 2
206010003074 arachnoiditis Diseases 0.000 claims description 2
208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
239000003543 catechol methyltransferase inhibitor Substances 0.000 claims description 2
210000003169 central nervous system Anatomy 0.000 claims description 2
239000000064 cholinergic agonist Substances 0.000 claims description 2
239000000544 cholinesterase inhibitor Substances 0.000 claims description 2
LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 claims description 2
229960005156 digoxin Drugs 0.000 claims description 2
LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 claims description 2
208000035475 disorder Diseases 0.000 claims description 2
229960001089 dobutamine Drugs 0.000 claims description 2
229940052760 dopamine agonists Drugs 0.000 claims description 2
239000003136 dopamine receptor stimulating agent Substances 0.000 claims description 2
229910052731 fluorine Inorganic materials 0.000 claims description 2
125000001153 fluoro group Chemical group F* 0.000 claims description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 2
230000036543 hypotension Effects 0.000 claims description 2
239000002955 immunomodulating agent Substances 0.000 claims description 2
229940121354 immunomodulator Drugs 0.000 claims description 2
208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims description 2
239000003112 inhibitor Substances 0.000 claims description 2
206010022437 insomnia Diseases 0.000 claims description 2
229960001388 interferon-beta Drugs 0.000 claims description 2
206010023497 kuru Diseases 0.000 claims description 2
208000014817 lissencephaly spectrum disease Diseases 0.000 claims description 2
208000002780 macular degeneration Diseases 0.000 claims description 2
230000003340 mental effect Effects 0.000 claims description 2
230000000394 mitotic effect Effects 0.000 claims description 2
230000003955 neuronal function Effects 0.000 claims description 2
125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 claims description 2
229920000155 polyglutamine Polymers 0.000 claims description 2
108010040003 polyglutamine Proteins 0.000 claims description 2
208000000170 postencephalitic Parkinson disease Diseases 0.000 claims description 2
206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 claims description 2
208000001381 pseudotumor cerebri Diseases 0.000 claims description 2
239000000018 receptor agonist Substances 0.000 claims description 2
229940044601 receptor agonist Drugs 0.000 claims description 2
201000000980 schizophrenia Diseases 0.000 claims description 2
239000000952 serotonin receptor agonist Substances 0.000 claims description 2
230000035939 shock Effects 0.000 claims description 2
LVRAKYNQYKVPIK-BSPYNPCNSA-N smilagenin acetate Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@@H](C[C@H]4CC[C@H]3[C@@H]2C1)OC(C)=O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 LVRAKYNQYKVPIK-BSPYNPCNSA-N 0.000 claims description 2
208000020431 spinal cord injury Diseases 0.000 claims description 2
125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims description 2
230000000472 traumatic effect Effects 0.000 claims description 2
208000009999 tuberous sclerosis Diseases 0.000 claims description 2
231100000216 vascular lesion Toxicity 0.000 claims description 2
201000002498 viral encephalitis Diseases 0.000 claims description 2
UZVNCLCLJHPHIF-NOJKMYKQSA-J zinc;(1e)-2-(ethylcarbamoylamino)-n-methoxy-2-oxoethanimidoyl cyanide;manganese(2+);n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[Zn+2].[S-]C(=S)NCCNC([S-])=S.[S-]C(=S)NCCNC([S-])=S.CCNC(=O)NC(=O)C(\C#N)=N\OC UZVNCLCLJHPHIF-NOJKMYKQSA-J 0.000 claims description 2
239000013543 active substance Substances 0.000 claims 5
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims 2
102000003678 AMPA Receptors Human genes 0.000 claims 1
108090000078 AMPA Receptors Proteins 0.000 claims 1
101150051188 Adora2a gene Proteins 0.000 claims 1
239000002126 C01EB10 - Adenosine Substances 0.000 claims 1
206010008096 Cerebral atrophy Diseases 0.000 claims 1
208000026072 Motor neurone disease Diseases 0.000 claims 1
239000011149 active material Substances 0.000 claims 1
229960005305 adenosine Drugs 0.000 claims 1
230000000747 cardiac effect Effects 0.000 claims 1
230000000994 depressogenic effect Effects 0.000 claims 1
235000011835 quiches Nutrition 0.000 claims 1
239000002464 receptor antagonist Substances 0.000 claims 1
229940044551 receptor antagonist Drugs 0.000 claims 1
229940125723 sedative agent Drugs 0.000 claims 1
239000000932 sedative agent Substances 0.000 claims 1
238000011282 treatment Methods 0.000 abstract description 27
230000001537 neural effect Effects 0.000 abstract description 3
238000002560 therapeutic procedure Methods 0.000 abstract description 3
230000006735 deficit Effects 0.000 abstract description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 72
229930195712 glutamate Natural products 0.000 description 72
230000000694 effects Effects 0.000 description 44
241000700159 Rattus Species 0.000 description 43
210000002569 neuron Anatomy 0.000 description 30
210000004556 brain Anatomy 0.000 description 19
102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 17
108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 17
210000002161 motor neuron Anatomy 0.000 description 16
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
230000007423 decrease Effects 0.000 description 14
230000002441 reversible effect Effects 0.000 description 14
241000699670 Mus sp. Species 0.000 description 13
238000000338 in vitro Methods 0.000 description 13
238000012360 testing method Methods 0.000 description 13
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical group NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 12
210000002241 neurite Anatomy 0.000 description 12
239000002253 acid Substances 0.000 description 11
208000010877 cognitive disease Diseases 0.000 description 11
238000001727 in vivo Methods 0.000 description 11
230000000324 neuroprotective effect Effects 0.000 description 11
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 10
238000002474 experimental method Methods 0.000 description 10
208000024891 symptom Diseases 0.000 description 10
102000003855 L-lactate dehydrogenase Human genes 0.000 description 9
108700023483 L-lactate dehydrogenases Proteins 0.000 description 9
239000002585 base Substances 0.000 description 9
210000003618 cortical neuron Anatomy 0.000 description 9
230000006378 damage Effects 0.000 description 9
102000003952 Caspase 3 Human genes 0.000 description 8
108090000397 Caspase 3 Proteins 0.000 description 8
239000002609 medium Substances 0.000 description 8
239000002581 neurotoxin Substances 0.000 description 8
231100000618 neurotoxin Toxicity 0.000 description 8
230000009467 reduction Effects 0.000 description 8
230000004044 response Effects 0.000 description 8
208000024827 Alzheimer disease Diseases 0.000 description 7
DWCSNWXARWMZTG-UHFFFAOYSA-N Trigonegenin A Natural products CC1C(C2(CCC3C4(C)CCC(O)C=C4CCC3C2C2)C)C2OC11CCC(C)CO1 DWCSNWXARWMZTG-UHFFFAOYSA-N 0.000 description 7
WQLVFSAGQJTQCK-VKROHFNGSA-N diosgenin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)CC4=CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 WQLVFSAGQJTQCK-VKROHFNGSA-N 0.000 description 7
210000005064 dopaminergic neuron Anatomy 0.000 description 7
238000002360 preparation method Methods 0.000 description 7
108010090849 Amyloid beta-Peptides Proteins 0.000 description 6
102000013455 Amyloid beta-Peptides Human genes 0.000 description 6
101710138657 Neurotoxin Proteins 0.000 description 6
GMBQZIIUCVWOCD-WWASVFFGSA-N Sarsapogenine Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)C[C@H]4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@H](C)CO1 GMBQZIIUCVWOCD-WWASVFFGSA-N 0.000 description 6
210000004027 cell Anatomy 0.000 description 6
229960003638 dopamine Drugs 0.000 description 6
239000000463 material Substances 0.000 description 6
208000015122 neurodegenerative disease Diseases 0.000 description 6
239000000546 pharmaceutical excipient Substances 0.000 description 6
230000002829 reductive effect Effects 0.000 description 6
150000007949 saponins Chemical class 0.000 description 6
235000017709 saponins Nutrition 0.000 description 6
230000004083 survival effect Effects 0.000 description 6
206010012289 Dementia Diseases 0.000 description 5
DKMROQRQHGEIOW-UHFFFAOYSA-N Diethyl succinate Chemical compound CCOC(=O)CCC(=O)OCC DKMROQRQHGEIOW-UHFFFAOYSA-N 0.000 description 5
102000015554 Dopamine receptor Human genes 0.000 description 5
108050004812 Dopamine receptor Proteins 0.000 description 5
238000012404 In vitro experiment Methods 0.000 description 5
241001465754 Metazoa Species 0.000 description 5
239000000969 carrier Substances 0.000 description 5
239000010949 copper Substances 0.000 description 5
230000003291 dopaminomimetic effect Effects 0.000 description 5
229960005309 estradiol Drugs 0.000 description 5
230000003551 muscarinic effect Effects 0.000 description 5
230000003961 neuronal insult Effects 0.000 description 5
108090000623 proteins and genes Proteins 0.000 description 5
239000002904 solvent Substances 0.000 description 5
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 4
102000019197 Superoxide Dismutase Human genes 0.000 description 4
108010012715 Superoxide dismutase Proteins 0.000 description 4
244000193174 agave Species 0.000 description 4
230000002424 anti-apoptotic effect Effects 0.000 description 4
230000006907 apoptotic process Effects 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
210000004978 chinese hamster ovary cell Anatomy 0.000 description 4
229910052802 copper Inorganic materials 0.000 description 4
235000013305 food Nutrition 0.000 description 4
238000009472 formulation Methods 0.000 description 4
125000000524 functional group Chemical group 0.000 description 4
239000003102 growth factor Substances 0.000 description 4
239000001963 growth medium Substances 0.000 description 4
238000011534 incubation Methods 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
239000013642 negative control Substances 0.000 description 4
230000002265 prevention Effects 0.000 description 4
125000006239 protecting group Chemical group 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
210000001364 upper extremity Anatomy 0.000 description 4
230000003612 virological effect Effects 0.000 description 4
241000196324 Embryophyta Species 0.000 description 3
101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 description 3
206010056677 Nerve degeneration Diseases 0.000 description 3
208000028389 Nerve injury Diseases 0.000 description 3
206010031127 Orthostatic hypotension Diseases 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
230000002164 acetylcholinergic effect Effects 0.000 description 3
230000032683 aging Effects 0.000 description 3
230000008901 benefit Effects 0.000 description 3
102000016966 beta-2 Adrenergic Receptors Human genes 0.000 description 3
108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
230000001054 cortical effect Effects 0.000 description 3
208000037765 diseases and disorders Diseases 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
239000012737 fresh medium Substances 0.000 description 3
238000010874 in vitro model Methods 0.000 description 3
239000007788 liquid Substances 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
230000008764 nerve damage Effects 0.000 description 3
210000004498 neuroglial cell Anatomy 0.000 description 3
230000000508 neurotrophic effect Effects 0.000 description 3
238000010534 nucleophilic substitution reaction Methods 0.000 description 3
230000003287 optical effect Effects 0.000 description 3
102000045222 parkin Human genes 0.000 description 3
229960005190 phenylalanine Drugs 0.000 description 3
239000013641 positive control Substances 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
241000894007 species Species 0.000 description 3
238000012453 sprague-dawley rat model Methods 0.000 description 3
PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 2
JHNLZOVBAQWGQU-UHFFFAOYSA-N 380814_sial Chemical compound CS(O)(=O)=O.O=P(=O)OP(=O)=O JHNLZOVBAQWGQU-UHFFFAOYSA-N 0.000 description 2
241000605447 Anemarrhena Species 0.000 description 2
241000605422 Asparagus asparagoides Species 0.000 description 2
235000005340 Asparagus officinalis Nutrition 0.000 description 2
206010003805 Autism Diseases 0.000 description 2
208000020706 Autistic disease Diseases 0.000 description 2
102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 2
108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 2
NKKIKSVUOQQLHL-DMTHEBMLSA-N C[C@H](O)[C@H](O)[C@@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O Chemical compound C[C@H](O)[C@H](O)[C@@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O NKKIKSVUOQQLHL-DMTHEBMLSA-N 0.000 description 2
FMGYKKMPNATWHP-UHFFFAOYSA-N Cyperquat Chemical compound C1=C[N+](C)=CC=C1C1=CC=CC=C1 FMGYKKMPNATWHP-UHFFFAOYSA-N 0.000 description 2
239000001653 FEMA 3120 Substances 0.000 description 2
206010019280 Heart failures Diseases 0.000 description 2
206010020751 Hypersensitivity Diseases 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
206010029350 Neurotoxicity Diseases 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
206010039966 Senile dementia Diseases 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
206010044221 Toxic encephalopathy Diseases 0.000 description 2
241001532059 Yucca Species 0.000 description 2
235000004552 Yucca aloifolia Nutrition 0.000 description 2
235000012044 Yucca brevifolia Nutrition 0.000 description 2
235000017049 Yucca glauca Nutrition 0.000 description 2
229960004373 acetylcholine Drugs 0.000 description 2
125000004442 acylamino group Chemical group 0.000 description 2
230000010933 acylation Effects 0.000 description 2
238000005917 acylation reaction Methods 0.000 description 2
125000003545 alkoxy group Chemical group 0.000 description 2
125000003277 amino group Chemical group 0.000 description 2
229930191283 anemarrhena Natural products 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
229940077737 brain-derived neurotrophic factor Drugs 0.000 description 2
125000001246 bromo group Chemical group Br* 0.000 description 2
230000008859 change Effects 0.000 description 2
125000001309 chloro group Chemical group Cl* 0.000 description 2
230000001713 cholinergic effect Effects 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
230000003930 cognitive ability Effects 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
125000000753 cycloalkyl group Chemical group 0.000 description 2
230000034994 death Effects 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
238000013461 design Methods 0.000 description 2
238000009510 drug design Methods 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
230000006870 function Effects 0.000 description 2
210000001320 hippocampus Anatomy 0.000 description 2
230000001771 impaired effect Effects 0.000 description 2
230000007794 irritation Effects 0.000 description 2
239000003550 marker Substances 0.000 description 2
206010027175 memory impairment Diseases 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
239000002207 metabolite Substances 0.000 description 2
208000027061 mild cognitive impairment Diseases 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000007514 neuronal growth Effects 0.000 description 2
230000007135 neurotoxicity Effects 0.000 description 2
231100000228 neurotoxicity Toxicity 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
239000002245 particle Substances 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
230000000750 progressive effect Effects 0.000 description 2
238000011321 prophylaxis Methods 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
230000007017 scission Effects 0.000 description 2
238000000926 separation method Methods 0.000 description 2
239000011734 sodium Substances 0.000 description 2
230000003595 spectral effect Effects 0.000 description 2
150000003431 steroids Chemical class 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
239000000758 substrate Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
239000003826 tablet Substances 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
KUXLVFFUSZCVHJ-YWDSYVAPSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-methylbutanoyl]amino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(C)=O KUXLVFFUSZCVHJ-YWDSYVAPSA-N 0.000 description 1
JETBVOLWZWPMKR-WCCKRBBISA-N (2s)-2-amino-3-methylbutanoic acid;hydrochloride Chemical compound Cl.CC(C)[C@H](N)C(O)=O JETBVOLWZWPMKR-WCCKRBBISA-N 0.000 description 1
ZAIZDXVMSSDZFA-QRPNPIFTSA-N (2s)-2-amino-3-phenylpropanoic acid;hydrochloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CC=CC=C1 ZAIZDXVMSSDZFA-QRPNPIFTSA-N 0.000 description 1
OSUIUMQSEFFIKM-WCCKRBBISA-N (2s)-2-amino-4-methylsulfanylbutanoic acid;hydrochloride Chemical compound Cl.CSCC[C@H](N)C(O)=O OSUIUMQSEFFIKM-WCCKRBBISA-N 0.000 description 1
ILYVXUGGBVATGA-DKWTVANSSA-N (2s)-2-aminopropanoic acid;hydrochloride Chemical compound Cl.C[C@H](N)C(O)=O ILYVXUGGBVATGA-DKWTVANSSA-N 0.000 description 1
XIIAYQZJNBULGD-UHFFFAOYSA-N (5alpha)-cholestane Natural products C1CC2CCCCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 XIIAYQZJNBULGD-UHFFFAOYSA-N 0.000 description 1
TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 1
239000000774 AMPA receptor agonist Substances 0.000 description 1
101001023097 Actinia equina Delta-actitoxin-Aeq2a Proteins 0.000 description 1
229940123702 Adenosine A2a receptor antagonist Drugs 0.000 description 1
108060003345 Adrenergic Receptor Proteins 0.000 description 1
102000017910 Adrenergic receptor Human genes 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
101000685065 Androctonus crassicauda Alpha-toxin Ac1 Proteins 0.000 description 1
101100424823 Arabidopsis thaliana TDT gene Proteins 0.000 description 1
101000685088 Buthus occitanus tunetanus Alpha-toxin Bot1 Proteins 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
102000011727 Caspases Human genes 0.000 description 1
108010076667 Caspases Proteins 0.000 description 1
101000685057 Centruroides limpidus Beta-toxin Cll1m Proteins 0.000 description 1
101000685076 Centruroides sculpturatus Toxin CsEv1 Proteins 0.000 description 1
101000685082 Centruroides tecomanus Beta-toxin Ct1a Proteins 0.000 description 1
102000009660 Cholinergic Receptors Human genes 0.000 description 1
108010009685 Cholinergic Receptors Proteins 0.000 description 1
108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
241001573498 Compacta Species 0.000 description 1
101150049660 DRD2 gene Proteins 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
239000004593 Epoxy Substances 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
208000007976 Ketosis Diseases 0.000 description 1
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
JPIJQSOTBSSVTP-STHAYSLISA-N L-threonic acid Chemical compound OC[C@H](O)[C@@H](O)C(O)=O JPIJQSOTBSSVTP-STHAYSLISA-N 0.000 description 1
101000783410 Laticauda semifasciata Alpha-elapitoxin-Ls2a Proteins 0.000 description 1
208000009829 Lewy Body Disease Diseases 0.000 description 1
201000002832 Lewy body dementia Diseases 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
206010028289 Muscle atrophy Diseases 0.000 description 1
102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 1
108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 1
102100029268 Neurotrophin-3 Human genes 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
102000007399 Nuclear hormone receptor Human genes 0.000 description 1
108020005497 Nuclear hormone receptor Proteins 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
229930182558 Sterol Natural products 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
229940123445 Tricyclic antidepressant Drugs 0.000 description 1
201000004810 Vascular dementia Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
208000037919 acquired disease Diseases 0.000 description 1
150000001263 acyl chlorides Chemical class 0.000 description 1
150000001266 acyl halides Chemical class 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000002467 adenosine A2a receptor antagonist Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
238000012382 advanced drug delivery Methods 0.000 description 1
230000002411 adverse Effects 0.000 description 1
150000001323 aldoses Chemical class 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
125000004466 alkoxycarbonylamino group Chemical group 0.000 description 1
125000003282 alkyl amino group Chemical group 0.000 description 1
SHZGCJCMOBCMKK-DVKNGEFBSA-N alpha-D-quinovopyranose Chemical compound C[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O SHZGCJCMOBCMKK-DVKNGEFBSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
239000000908 ammonium hydroxide Substances 0.000 description 1
108010064397 amyloid beta-protein (1-40) Proteins 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
238000010171 animal model Methods 0.000 description 1
125000005239 aroylamino group Chemical group 0.000 description 1
229940009098 aspartate Drugs 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
230000006399 behavior Effects 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
244000309464 bull Species 0.000 description 1
125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
229940065144 cannabinoids Drugs 0.000 description 1
239000002775 capsule Substances 0.000 description 1
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
150000007942 carboxylates Chemical class 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
210000005056 cell body Anatomy 0.000 description 1
230000022131 cell cycle Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
210000003710 cerebral cortex Anatomy 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229960001231 choline Drugs 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
229940114081 cinnamate Drugs 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
238000003350 crude synaptosomal preparation Methods 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-L cysteinate(2-) Chemical compound [S-]CC(N)C([O-])=O XUJNEKJLAYXESH-UHFFFAOYSA-L 0.000 description 1
GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
238000004821 distillation Methods 0.000 description 1
POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
239000008298 dragée Substances 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000009509 drug development Methods 0.000 description 1
230000000459 effect on growth Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
210000001174 endocardium Anatomy 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
230000001076 estrogenic effect Effects 0.000 description 1
RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
239000000284 extract Substances 0.000 description 1
210000003414 extremity Anatomy 0.000 description 1
239000012467 final product Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
235000021550 forms of sugar Nutrition 0.000 description 1
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
239000012458 free base Substances 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
150000002243 furanoses Chemical class 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-M glutaminate Chemical compound [O-]C(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-M 0.000 description 1
239000008187 granular material Substances 0.000 description 1
230000012010 growth Effects 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
125000004356 hydroxy functional group Chemical group O* 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
230000003993 interaction Effects 0.000 description 1
FGKJLKRYENPLQH-UHFFFAOYSA-M isocaproate Chemical compound CC(C)CCC([O-])=O FGKJLKRYENPLQH-UHFFFAOYSA-M 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
150000002584 ketoses Chemical class 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
229940070765 laurate Drugs 0.000 description 1
238000000670 ligand binding assay Methods 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-M lysinate Chemical compound NCCCCC(N)C([O-])=O KDXKERNSBIXSRK-UHFFFAOYSA-M 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000003446 memory effect Effects 0.000 description 1
230000006993 memory improvement Effects 0.000 description 1
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
229910052987 metal hydride Inorganic materials 0.000 description 1
150000004681 metal hydrides Chemical class 0.000 description 1
238000002156 mixing Methods 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000003387 muscular Effects 0.000 description 1
229940105132 myristate Drugs 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
230000032405 negative regulation of neuron apoptotic process Effects 0.000 description 1
230000009826 neoplastic cell growth Effects 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
210000001577 neostriatum Anatomy 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
230000000626 neurodegenerative effect Effects 0.000 description 1
230000014511 neuron projection development Effects 0.000 description 1
230000005015 neuronal process Effects 0.000 description 1
230000006576 neuronal survival Effects 0.000 description 1
230000004112 neuroprotection Effects 0.000 description 1
229960002715 nicotine Drugs 0.000 description 1
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
108020004017 nuclear receptors Proteins 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
238000000399 optical microscopy Methods 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000008188 pellet Substances 0.000 description 1
125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
239000002304 perfume Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
229940049953 phenylacetate Drugs 0.000 description 1
WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-M phenylalaninate Chemical compound [O-]C(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-M 0.000 description 1
125000001557 phthalyl group Chemical group C(=O)(O)C1=C(C(=O)*)C=CC=C1 0.000 description 1
239000000419 plant extract Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-M prolinate Chemical compound [O-]C(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-M 0.000 description 1
125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
238000000746 purification Methods 0.000 description 1
150000003214 pyranose derivatives Chemical group 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000011552 rat model Methods 0.000 description 1
238000011084 recovery Methods 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000001226 reprecipitation Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
230000001953 sensory effect Effects 0.000 description 1
210000000697 sensory organ Anatomy 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-M serinate Chemical compound OCC(N)C([O-])=O MTCFGRXMJLQNBG-UHFFFAOYSA-M 0.000 description 1
239000012679 serum free medium Substances 0.000 description 1
101150062190 sod1 gene Proteins 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
150000003432 sterols Chemical class 0.000 description 1
235000003702 sterols Nutrition 0.000 description 1
210000003523 substantia nigra Anatomy 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
238000012353 t test Methods 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
229940022036 threonate Drugs 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
238000012549 training Methods 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000000844 transformation Methods 0.000 description 1
238000011830 transgenic mouse model Methods 0.000 description 1
239000003029 tricyclic antidepressant agent Substances 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-M tryptophanate Chemical compound C1=CC=C2C(CC(N)C([O-])=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-M 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-L tyrosinate(2-) Chemical compound [O-]C(=O)C(N)CC1=CC=C([O-])C=C1 OUYCCCASQSFEME-UHFFFAOYSA-L 0.000 description 1
229940070710 valerate Drugs 0.000 description 1
NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
XIIAYQZJNBULGD-CJPSHIORSA-N β-cholestane Chemical compound C([C@H]1CC2)CCC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 XIIAYQZJNBULGD-CJPSHIORSA-N 0.000 description 1

Images

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Pulmonology (AREA)
Hospice & Palliative Care (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Steroid Compounds (AREA)
Catalysts (AREA)

KR1020107017081A 2002-03-27 2003-03-27 사포게닌 및 그 유도체의 치료 방법 및 용도 KR20100093621A (ko)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
ARP020101170		2002-03-27
ARP020101170A AR033079A1 (es)	2001-03-28	2002-03-27	Derivados de sapogeninas, sintesis y uso, y metodos en base a su uso
US36817802P	2002-03-28	2002-03-28
PCT/GB2002/001578 WO2002079221A2 (en)	2001-03-28	2002-03-28	Sapogenin derivatives, their synthesis and use
WOPCT/GB02/01578		2002-03-28
US60/368,178		2002-03-28

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
KR1020087007136A Division KR20080031062A (ko)	2002-03-27	2003-03-27	사포게닌 및 그 유도체의 치료 방법 및 용도

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
KR1020127008441A Division KR20120128596A (ko)	2002-03-27	2003-03-27	사포게닌 및 그 유도체의 치료 방법 및 용도

Publications (1)

Publication Number	Publication Date
KR20100093621A true KR20100093621A (ko)	2010-08-25

Family

ID=30001210

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
KR1020107017081A KR20100093621A (ko)	2002-03-27	2003-03-27	사포게닌 및 그 유도체의 치료 방법 및 용도

Country Status (10)

Country	Link
KR (1)	KR20100093621A (xx)
CN (1)	CN1642558B (xx)
AT (1)	ATE424211T1 (xx)
IL (1)	IL164161A0 (xx)
NZ (2)	NZ547344A (xx)
PE (1)	PE20040306A1 (xx)
PL (1)	PL213697B1 (xx)
RU (1)	RU2332999C2 (xx)
TW (1)	TWI329016B (xx)
WO (1)	WO2003082893A2 (xx)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6861788B2 (en) *	2003-06-03	2005-03-01	Motorola, Inc.	Switchable display/mirror method and apparatus
FR2868700B1 (fr) *	2004-04-09	2008-09-26	Michel Coisy	Utilisation de la dopamine ou de ses precurseurs biologiques contre l'algoneurodystrphie.
GB0409567D0 (en)	2004-04-28	2004-06-02	Phytopharm Plc	Chemical compounds
GB0424528D0 (en) *	2004-11-05	2004-12-08	Phytopharm Plc	Chemical compounds
CN101296703B (zh)	2005-10-28	2011-07-27	金善砺	薯蓣科提取物及包含此提取物、用于预防或治疗外周神经疾病的组合物
EA201190115A1 (ru)	2009-01-24	2012-02-28	ФИТОФАРМ ПиЭлСи	Лечение расстройств, опосредованных нейротрофическим фактором
JP2013543482A (ja) *	2010-07-20	2013-12-05	ファイトファームピーエルシー	Ｌ−ドーパ、ドーパミン作動薬及び／又はドーパミン賦活剤により誘発される疾患の処置
BR112014005373B1 (pt)	2011-09-08	2022-04-19	Sage Therapeutics, Inc	Compostos esteróides neuroativos, composições e usos destes
CU20110244A7 (es) *	2011-12-27	2013-08-29	Ct De Investigación Y Desarrollo De Medicamentos Cidem	Sistemas espiroesteroidales con efectos neuroactivos y anti-inflamatorios
WO2013149580A1 (en) *	2012-04-03	2013-10-10	Chiming Che	Timosaponin compounds
IL280068B1 (en)	2013-03-13	2025-02-01	Sage Therapeutics Inc	Neuroactivity is modulated at position 24 by hydroxy and alkyl/alkenyl/alkynyl 3beta–hydroxy–cholane and 3beta–hydroxy–chol–5–ene derivatives
CN103232520A (zh) *	2013-05-13	2013-08-07	中国药科大学	一种螺甾类化合物、其制备方法及医药用途
JP6628745B2 (ja)	2014-06-18	2020-01-15	セージセラピューティクス，インコーポレイテッド	オキシステロールおよびその使用方法
RS62220B1 (sr)	2015-07-06	2021-09-30	Sage Therapeutics Inc	Oksisteroli i postupci njihovog korišćenja
NZ738582A (en)	2015-07-06	2024-10-25	Sage Therapeutics Inc	Oxysterols and methods of use thereof
PH12018500065B1 (en)	2015-07-06	2022-11-04	Sage Therapeutics Inc	Oxysterols and methods of use thereof
PT3436022T (pt)	2016-04-01	2022-07-04	Sage Therapeutics Inc	Oxisteróis e métodos de utilização dos mesmos
WO2017193046A1 (en)	2016-05-06	2017-11-09	Sage Therapeutics, Inc.	Oxysterols and methods of use thereof
TWI752976B (zh)	2016-07-07	2022-01-21	美商賽吉醫療公司	氧固醇(oxysterol)及其使用方法
PT3519422T (pt)	2016-09-30	2022-12-05	Sage Therapeutics Inc	Oxisteróis substituídos em c7 e métodos como moduladores nmda
DK3529257T3 (da)	2016-10-18	2023-08-07	Sage Therapeutics Inc	Oxysteroler og fremgangsmåder til anvendelse deraf
EP4105223A1 (en)	2016-10-18	2022-12-21	Sage Therapeutics, Inc.	Oxysterols and methods of use thereof
CN108264535A (zh) *	2016-12-30	2018-07-10	中国科学院上海药物研究所	一种抗抑郁化合物及其制备方法和应用
RU2635485C1 (ru) *	2017-03-21	2017-11-13	Федеральное государственное автономное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации	Способ лечения атрофии зрительного нерва после черепно-мозговой травмы
CN109988218B (zh) *	2017-12-29	2022-11-25	中国科学院上海药物研究所	一种菝葜皂苷元衍生物及其制备方法和应用
EP3572085A1 (en)	2018-05-25	2019-11-27	Neuro-Sys	Synergestic combination composition comprising a steroidal saponin, a first polyphenolic compound and optionnaly a second polyphenolic compound
CN112457362B (zh) *	2019-09-06	2023-09-19	上海青东生物科技有限公司	一种卤代四环三萜衍生物及其制备与应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3416112A1 (de) *	1984-04-30	1985-10-31	Roecar Holdings (Netherlands Antilles) N.V., Willemstad, Curacao, Niederländische Antillen	Verwendung von sterolinen und spiroketalinen als lipoxygenaseregulatoren
US4680289A (en) *	1985-06-05	1987-07-14	Progenics, Inc.	Treatment of obesity and diabetes using sapogenins
JPH05246866A (ja) *	1992-03-06	1993-09-24	Ruibosuteii Japan:Kk	脳代謝促進・脳機能改善剤
DE4303214A1 (de) *	1993-02-04	1994-08-11	Wolfgang Marks	Behandlung von Erkrankungen viraler, viroidaler oder onkogener Genese durch Steroid-Saponine oder deren Aglykone
TW479061B (en) *	1993-12-24	2002-03-11	Mitsubishi Chem Corp	Sialic acid derivatives
JPH092956A (ja) *	1995-06-22	1997-01-07	Mitsubishi Chem Corp	神経障害の治療、予防薬
JPH092957A (ja) *	1995-06-22	1997-01-07	Mitsubishi Chem Corp	末梢性神経障害の治療、予防薬
US6046185A (en) *	1996-07-11	2000-04-04	Inflazyme Pharmaceuticals Ltd.	6,7-oxygenated steroids and uses related thereto
CN1131237C (zh) *	1997-09-26	2003-12-17	中国人民解放军军事医学科学院放射医学研究所	甾体皂甙防治老年性痴呆的用途及新的甾体皂甙
JP3768100B2 (ja) *	1998-03-26	2006-04-19	ファイトファーム・ピーエルシー	アルツハイマー病を治療するためのステロイドサポゲニンとその誘導体
GB9923076D0 (en) *	1999-09-29	1999-12-01	Phytopharm Plc	Sapogenin derivatives and their use
GB9923078D0 (en) *	1999-09-29	1999-12-01	Phytopharm Plc	Sapogenin derivatives and their use
GB9923077D0 (en) *	1999-09-29	1999-12-01	Phytopharm Plc	Sapogenin derivatives and their use
GB0000228D0 (en) *	2000-01-06	2000-03-01	Phytopharm Plc	Fluoro substituted sapogenins and their use
JP2002030096A (ja) *	2000-07-11	2002-01-29	Kyorin Pharmaceut Co Ltd	神経細胞突起再生剤及びその製造方法
AU2003218180B2 (en) *	2002-03-15	2008-03-20	Georgetown University	Neuroprotective spirostenol pharmaceutical compositions

2003
- 2003-03-27 IL IL16416103A patent/IL164161A0/xx unknown
- 2003-03-27 PL PL372941A patent/PL213697B1/pl not_active IP Right Cessation
- 2003-03-27 KR KR1020107017081A patent/KR20100093621A/ko active IP Right Grant
- 2003-03-27 TW TW092106926A patent/TWI329016B/zh not_active IP Right Cessation
- 2003-03-27 NZ NZ547344A patent/NZ547344A/en unknown
- 2003-03-27 CN CN038071886A patent/CN1642558B/zh not_active Expired - Fee Related
- 2003-03-27 AT AT03722713T patent/ATE424211T1/de active
- 2003-03-27 WO PCT/GB2003/001380 patent/WO2003082893A2/en active Application Filing
- 2003-03-27 RU RU2004130281/15A patent/RU2332999C2/ru not_active IP Right Cessation
- 2003-03-27 NZ NZ547897A patent/NZ547897A/en unknown
- 2003-03-27 PE PE2003000315A patent/PE20040306A1/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
ATE424211T1 (de)	2009-03-15
WO2003082893A3 (en)	2004-04-15
RU2004130281A (ru)	2006-01-20
TW200400042A (en)	2004-01-01
CN1642558A (zh)	2005-07-20
NZ547897A (en)	2008-02-29
WO2003082893A8 (en)	2003-12-31
CN1642558B (zh)	2012-05-30
NZ547344A (en)	2007-11-30
IL164161A0 (en)	2005-12-18
PL213697B1 (pl)	2013-04-30
PE20040306A1 (es)	2004-05-29
WO2003082893A2 (en)	2003-10-09
PL372941A1 (en)	2005-08-08
RU2332999C2 (ru)	2008-09-10
TWI329016B (en)	2010-08-21

Publication	Publication Date	Title
KR20100093621A (ko)	2010-08-25	사포게닌 및 그 유도체의 치료 방법 및 용도
US20110190249A1 (en)	2011-08-04	Therapeutic methods and uses of sapogenins and their derivatives
RU2325396C2 (ru)	2008-05-27	Производные 5бета-сапогенина и псевдосапогенина и их применение при лечении деменции
KR100632052B1 (ko)	2006-10-04	알츠하이머병을 치료하기 위한 스테로이드계 사포게닌 및 이의 유도체
KR20040007479A (ko)	2004-01-24	사포게닌 유도체, 이들의 합성법 및 용도, 및 그 용도에기초한 방법
JPH09165333A (ja)	1997-06-24	カプサイシン様応答のための可変スペクトルを有する化合物を含有する組成物
JP4970932B2 (ja)	2012-07-11	コレスト−４−エン−３−オンの誘導体の医薬としての使用、これらを含む医薬組成物、新規誘導体及びそれらの製造方法
CN101133075A (zh)	2008-02-27	用于治疗阿尔茨海默氏病和抑制β淀粉样肽生成的化合物
CA3100886C (en)	2023-06-06	Synergestic combination composition comprising a steroidal saponin, a first polyphenolic compound and a second polyphenolic compound
US20050130948A1 (en)	2005-06-16	Therapeutic methods and uses of sapogenins and their derivatives
KR20120128596A (ko)	2012-11-27	사포게닌 및 그 유도체의 치료 방법 및 용도
AU2003229877B2 (en)	2008-05-29	Theraputic methods and uses of sapogenins and their derivatives
KR20080031062A (ko)	2008-04-07	사포게닌 및 그 유도체의 치료 방법 및 용도
TWI357816B (en)	2012-02-11	Therapeutic methods and uses of sapogenins and the
WO2024242517A1 (ko)	2024-11-28	한약재 혼합물을 포함하는 비만 예방 또는 약학적 조성물 및 이를 포함하는 주사제
AU781810B2 (en)	2005-06-16	Steroidal sapogenins and their derivatives for treating Alzheimer's disease
US20170348340A1 (en)	2017-12-07	New c-glycosylpolyphenol antidiabetic agents, effect on glucose tolerance and interaction with beta-amyloid. therapeutic applications of the synthesized agent(s) and of genista tenera ethyl acetate extracts containing some of those agents

Legal Events

Date	Code	Title	Description
2010-07-29	A107	Divisional application of patent
2010-07-29	A201	Request for examination
2010-07-29	PA0104	Divisional application for international application	Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20100729 Application number text: 1020087007136 Filing date: 20080325
2010-07-29	PA0201	Request for examination
2010-08-25	PG1501	Laying open of application
2010-10-20	E902	Notification of reason for refusal
2010-10-20	PE0902	Notice of grounds for rejection	Comment text: Notification of reason for refusal Patent event date: 20101020 Patent event code: PE09021S01D
2011-04-20	AMND	Amendment
2011-11-29	E601	Decision to refuse application
2011-11-29	PE0601	Decision on rejection of patent	Patent event date: 20111129 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20101020 Comment text: Notification of reason for refusal Patent event code: PE06011S01I
2012-02-29	J201	Request for trial against refusal decision
2012-02-29	PJ0201	Trial against decision of rejection	Patent event date: 20120229 Comment text: Request for Trial against Decision on Refusal Patent event code: PJ02012R01D Patent event date: 20111129 Comment text: Decision to Refuse Application Patent event code: PJ02011S01I Appeal kind category: Appeal against decision to decline refusal Decision date: 20130603 Appeal identifier: 2012101002170 Request date: 20120229
2012-03-30	A107	Divisional application of patent
2012-03-30	AMND	Amendment
2012-03-30	PA0104	Divisional application for international application	Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20120330 Application number text: 1020087007136 Filing date: 20080325
2012-04-06	PB0901	Examination by re-examination before a trial	Comment text: Amendment to Specification, etc. Patent event date: 20120330 Patent event code: PB09011R02I Comment text: Request for Trial against Decision on Refusal Patent event date: 20120229 Patent event code: PB09011R01I Comment text: Amendment to Specification, etc. Patent event date: 20110420 Patent event code: PB09011R02I
2012-05-03	E90F	Notification of reason for final refusal
2012-05-03	PE0902	Notice of grounds for rejection	Comment text: Final Notice of Reason for Refusal Patent event date: 20120503 Patent event code: PE09021S02D
2013-06-03	B701	Decision to grant
2013-06-03	PB0701	Decision of registration after re-examination before a trial	Patent event date: 20130603 Comment text: Decision to Grant Registration Patent event code: PB07012S01D Patent event date: 20120406 Comment text: Transfer of Trial File for Re-examination before a Trial Patent event code: PB07011S01I
2014-03-03	PC1904	Unpaid initial registration fee